Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS) engages in the research, development, production and sale of pharmaceuticals and health products with a focus on marine biopharmaceuticals; the company manufactures active pharmaceutical ingredients (APIs) including glucosamine hydrochloride, gastrodin, ribavirin and azathioprine; finished dosage forms such as injections (e.g., torasemide injection, hydrochloride dopamine-betahistine injection), capsules, tablets, granules and external medicines; and over 90 types of products covering arthritis treatments, diuretics, brain nerve soothing, anti-virus and anti-tumor therapies. Founded in 1966 as Wenzhou No. 3 Pharmaceutical Factory and renamed in April 2001, the company is headquartered in Shanghai with primary operations in Wenzhou, Zhejiang province, China; it serves domestic markets through a Shanghai marketing center, 14 regional offices and three provincial sales departments while exporting to over 20 countries in Europe, America, India, South Africa and Southeast Asia. Products hold international certifications from U.S. FDA, EU EMEA, Australia TGA, UK MHRA and Mexico COFEPRIS; the company operates GMP-standard workshops and pursues a "Two Strengths and One Scale" initiative for Asia's largest glucosamine API (2,000 tons annually) and super fish oil (1,000 tons) production base during the 14th Five-Year Plan. Recent developments include approval of fish oil EPA soft capsules in September 2025, adding a key marine biomedicine product with ongoing distributor recruitment; completion of a 2024 share repurchase of 2.94% of shares (9.62 million shares); finalization in October 2025 of an asset sale to Ninghuai Pushun for RMB 114 million involving land transfer; passage of consistency evaluation for hydrochloride dopamine-betahistine injection; and a June 2024 asset acquisition by subsidiary Jiangsu Chengyi Pharmaceutical in Huai'an City.